Dr Tara Graff, MD

Medical professional dedicated to sharing knowledge and insights through educational videos.

Dr. Tara Graff describes the reduced need for subsequent therapies when using Pola-R-CHP in LBCL (Video 3/3)

POLARIX reduced risk subsequent therapies

Tara Graff, MD

Hematological Malignancies

Dr. Tara Graff reviews the efficacy of Pola-R-CHP in select LBCL subgroups (Video 2/3)

POLARIX subgroups

Tara Graff, MD

Hematological Malignancies

Dr. Tara Graff discusses the 5-year efficacy of Pola-R-CHP in LBCL (Video 1/3)

POLARIX 5 year efficacy

Tara Graff, MD

Hematological Malignancies

Dr. Tara Graff discusses operationalizing bispecifics into community practice (video 3/3)

Mosun-operationalizing

Tara Graff, MD

Hematological Malignancies

$Dr. Tara Graff discusses the dosing and administration of mosunetuzumab in relapsed/refractory follicular lymphoma along with recent data on the subcutaneous formulation. (Video 2/3)$

Dr. Tara Graff discusses the dosing and administration of mosunetuzumab in relapsed/refractory follicular lymphoma along with recent data on the subcutaneous formulation. (Video 2/3)

Mosun-SQ data

Tara Graff, MD

Hematological Malignancies

$Dr. Tara Graff discusses the recent four-year follow up data from the phase II study of mosunetuzumab in relapsed/refractory follicular lymphoma (video 1/3).$

Dr. Tara Graff discusses the recent four-year follow up data from the phase II study of mosunetuzumab in relapsed/refractory follicular lymphoma (video 1/3).

Mosun-4 year FU

Tara Graff, MD

Hematological Malignancies

IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

Dr Tara Graff, MD

Medical professional dedicated to sharing knowledge and insights through educational videos.

Dr. Tara Graff describes the reduced need for subsequent therapies when using Pola-R-CHP in LBCL (Video 3/3)

POLARIX reduced risk subsequent therapies

Tara Graff, MD

Hematological Malignancies

Dr. Tara Graff reviews the efficacy of Pola-R-CHP in select LBCL subgroups (Video 2/3)

POLARIX subgroups

Tara Graff, MD

Hematological Malignancies

Dr. Tara Graff discusses the 5-year efficacy of Pola-R-CHP in LBCL (Video 1/3)

POLARIX 5 year efficacy

Tara Graff, MD

Hematological Malignancies

Dr. Tara Graff discusses operationalizing bispecifics into community practice (video 3/3)

Mosun-operationalizing

Tara Graff, MD

Hematological Malignancies

$Dr. Tara Graff discusses the dosing and administration of mosunetuzumab in relapsed/refractory follicular lymphoma along with recent data on the subcutaneous formulation. (Video 2/3)$

Dr. Tara Graff discusses the dosing and administration of mosunetuzumab in relapsed/refractory follicular lymphoma along with recent data on the subcutaneous formulation. (Video 2/3)

Mosun-SQ data

Tara Graff, MD

Hematological Malignancies

$Dr. Tara Graff discusses the recent four-year follow up data from the phase II study of mosunetuzumab in relapsed/refractory follicular lymphoma (video 1/3).$

Dr. Tara Graff discusses the recent four-year follow up data from the phase II study of mosunetuzumab in relapsed/refractory follicular lymphoma (video 1/3).

Mosun-4 year FU

Tara Graff, MD

Hematological Malignancies

IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America